Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects

AAPS Journal

Volumn 13, Issue 4, 2011, Pages 650-661

  Budha, Nageshwar R ^a,c   Kovar, Andreas ^b   Meibohm, Bernd ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b MERCK KGAA   (Germany)

^c GENENTECH INC   (United States)

Author keywords

cell life span model; cell transit model; delayed response; pharmacodynamics; PK PD modeling

Indexed keywords

ANTIANEMIC AGENT; PLACEBO;

ACCURACY; ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ARTICLE; CELL SURVIVAL; CELL TRANSPORT; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DELAYED RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; ERYTHROCYTE COUNT; ESTIMATION ERROR; ESTIMATION STATUS; EXPERIMENTAL MODEL; FEMALE; GOODNESS OF FIT PLOT; MACACA FASCICULARIS; MALE; MATHEMATICAL MODEL; MODEL ESTIMATION TIME; MULTIPLE DRUG DOSE; NONHUMAN; PHARMACODYNAMICS; PREDICTION; TREATMENT RESPONSE; VISUAL PREDICTIVE CHECK;

ANIMALS; CELL AGING; ERYTHROPOIESIS; HEMATOPOIETIC CELL GROWTH FACTORS; MACACA FASCICULARIS; MODELS, BIOLOGICAL; PHARMACOKINETICS;

EID: 83555163598     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-011-9302-9     Document Type: Article

References (37)

1. LB Sheiner DR Stanski S Vozeh RD Miller J Ham 1979 Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine Clin Pharmacol Ther 25 358 371 761446 1:CAS:528:DyaE1MXhsl2qsro%3D (Pubitemid 9164953)
2. NL Dayneka V Garg WJ Jusko 1993 Comparison of four basic models of indirect pharmacodynamic responses J Pharmacokinet Biopharm 21 457 478 8133465 10.1007/BF01061691 1:CAS:528:DyaK2cXitlGhsb0%3D (Pubitemid 24025269)
3. LE Friberg A Henningsson H Maas L Nguyen MO Karlsson 2002 Model of chemotherapy-induced myelosuppression with parameter consistency across drugs J Clin Oncol 20 4713 4721 12488418 10.1200/JCO.2002.02.140 (Pubitemid 36025290)
4. M Loeffler K Pantel H Wulff HE Wichmann 1989 A mathematical model of erythropoiesis in mice and rats. Part 1: structure of the model Cell Tissue Kinet 22 13 30 2790923 1:STN:280:DyaK3c%2FgtlWlsQ%3D%3D (Pubitemid 19241657)
5. JJ Perez-Ruixo HC Kimko AT Chow V Piotrovsky W Krzyzanski WJ Jusko 2005 Population cell life span models for effects of drugs following indirect mechanisms of action J Pharmacokinet Pharmacodyn 32 767 793 16328102 10.1007/s10928-005-0019-1 (Pubitemid 41772357)
6. HE Wichmann M Loeffler K Pantel H Wulff 1989 A mathematical model of erythropoiesis in mice and rats. Part 2: stimulated erythropoiesis Cell Tissue Kinet 22 31 49 2790924 1:STN:280:DyaK3c%2FgtlWltg%3D%3D (Pubitemid 19241658)
7. H Wulff HE Wichmann K Pantel M Loeffler 1989 A mathematical model of erythropoiesis in mice and rats. Part 3: suppressed erythropoiesis Cell Tissue Kinet 22 51 61 2790925 1:STN:280:DyaK3c%2FgtlWltw%3D%3D (Pubitemid 19241659)
8. J Belair MC Mackey JM Mahaffy 1995 Age-structured and two-delay models for erythropoiesis Math Biosci 128 317 346 7606142 10.1016/0025-5564(94)00078-E 1:STN:280:DyaK2MzivF2jsg%3D%3D
9. B Agoram AC Heatherington MR Gastonguay 2006 Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy AAPS J 8 E552 E563 17025273 10.1208/aapsj080364 1:CAS:528:DC%2BD28XhtVGltLnK (Pubitemid 44399104)
10. R Ramakrishnan WK Cheung F Farrell L Joffee WJ Jusko 2003 Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys J Pharmacol Exp Ther 306 324 331 12676891 10.1124/jpet.102.047191 1:CAS:528:DC%2BD3sXkvF2ksrs%3D (Pubitemid 36734388)
11. W Krzyzanski JJ Perez-Ruixo A Vermeulen 2008 Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells J Pharmacokinet Pharmacodyn 35 349 377 18551354 10.1007/s10928-008-9092-6 1:CAS:528:DC%2BD1cXosVGiu7w%3D
12. W Krzyzanski S Woo WJ Jusko 2006 Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans J Pharmacokinet Pharmacodyn 33 125 166 16565883 10.1007/s10928-006-9007-3 1:CAS:528:DC%2BD28XjsVertrc%3D
13. S Woo W Krzyzanski WJ Jusko 2007 Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO) J Pharmacokinet Pharmacodyn 34 849 868 17943422 10.1007/s10928-007-9074-0 1:CAS:528:DC%2BD2sXhtlaqt7jE (Pubitemid 350165278)
14. MN Samtani JJ Perez-Ruixo KH Brown D Cerneus CJ Molloy 2009 Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects J Clin Pharmacol 49 336 350 19246731 10.1177/0091270008329559 1:CAS:528:DC%2BD1MXjslamtbY%3D
15. JJ Perez-Ruixo W Krzyzanski J Hing 2008 Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects Clin Pharmacokinet 47 399 415 18479174 10.2165/00003088-200847060-00004 1:CAS:528:DC%2BD1cXos1ehsrs%3D (Pubitemid 351685389)
16. N Velez de Mendizabal I Martinez-Forero MJ Garrido E Bandres J Garcia-Foncillas C Segura IF Troconiz 2010 A semi-physiological-based pharmacokinetic/pharmacodynamic model to describe the effects of topotecan on B-lymphocyte lineage cells Pharm Res 27 431 441 20101520 10.1007/s11095-009- 0025-x 1:CAS:528:DC%2BC3cXhtVWru78%3D
17. LA Harker LK Roskos UM Marzec RA Carter JK Cherry B Sundell EN Cheung D Terry W Sheridan 2000 Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers Blood 95 2514 2522 10753829 1:CAS:528:DC%2BD3cXisVaisbg%3D (Pubitemid 30210528)
18. J Ribbing B Hamren MK Svensson MO Karlsson 2010 A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes J Clin Pharmacol 50 861 872 20484615 10.1177/ 0091270009349711 1:CAS:528:DC%2BC3cXhtVCmsLzK
19. DE Uehlinger FA Gotch LB Sheiner 1992 A pharmacodynamic model of erythropoietin therapy for uremic anemia Clin Pharmacol Ther 51 76 89 1732079 10.1038/clpt.1992.10 1:STN:280:DyaK387hvFyqsg%3D%3D
20. B Hamren E Bjork M Sunzel M Karlsson 2008 Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment Clin Pharmacol Ther 84 228 235 18388881 10.1038/clpt.2008.2 1:CAS:528:DC%2BD1cXptlyktb8%3D
21. W de Winter J DeJongh T Post B Ploeger R Urquhart I Moules D Eckland M Danhof 2006 A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus J Pharmacokinet Pharmacodyn 33 313 343 16552630 10.1007/s10928-006-9008-2 (Pubitemid 44020384)
22. LE Friberg A Freijs M Sandstrom MO Karlsson 2000 Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats J Pharmacol Exp Ther 295 734 740 11046112 1:CAS:528:DC%2BD3cXnsl2kt7Y%3D
23. LK Roskos P Lum P Lockbaum G Schwab BB Yang 2006 Pharmacokinetic/ pharmacodynamic modeling of pegfilgrastim in healthy subjects J Clin Pharmacol 46 747 757 16809800 10.1177/0091270006288731 1:CAS:528:DC%2BD28XntlWgsbo%3D (Pubitemid 43882798)
24. S Woo W Krzyzanski AM Duliege RB Stead WJ Jusko 2008 Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers J Clin Pharmacol 48 43 52 18025524 10.1177/0091270007309702 1:CAS:528:DC%2BD1cXhtVGqtrc%3D (Pubitemid 350292274)
25. Holford N. Pharmacokinetic/pharmacodynamic models for red cell responses to hematopoietic stimulation with and without chemotherapy. American Society of Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, USA. March 2-5, 2005.
26. YM Wang W Krzyzanski S Doshi JJ Xiao JJ Perez-Ruixo AT Chow 2010 Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects Aaps J. 12 729 40 20963535 10.1208/s12248-010-9234-9 1:CAS:528:DC%2BC3cXhsFCqsbnK
27. K Brendel E Comets C Laffont C Laveille F Mentre 2006 Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide Pharm Res 23 2036 2049 16906454 10.1007/s11095-006-9067-5 1:CAS:528:DC%2BD28XptVaitL4%3D
28. E Comets K Brendel F Mentre 2008 Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R Comput Methods Programs Biomed 90 154 166 18215437 10.1016/j.cmpb.2007.12.002
29. S Elliott E Pham IC Macdougall 2008 Erythropoietins: a common mechanism of action Exp Hematol 36 1573 1584 18922615 10.1016/j.exphem.2008.08.003 1:CAS:528:DC%2BD1cXhtlyhsr%2FM
30. MO Karlsson V Molnar J Bergh A Freijs R Larsson 1998 A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression Clin Pharmacol Ther 63 11 25 9465838 10.1016/S0009-9236(98)90117-5 1:CAS:528:DyaK1cXhtVGhu74%3D (Pubitemid 28070182)
31. WJ Jusko HC Ko WF Ebling 1995 Convergence of direct and indirect pharmacodynamic response models J Pharmacokinet Biopharm 23 5 8 8576844 10.1007/BF02353781 1:CAS:528:DyaK28XkslWlug%3D%3D discussion 9-10
32. YN Sun WJ Jusko 1998 Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics J Pharm Sci 87 732 737 9607951 10.1021/js970414z 1:CAS:528:DyaK1cXivVOlu7Y%3D (Pubitemid 28268573)
33. DE Mager WJ Jusko 2008 Development of translational pharmacokinetic- pharmacodynamic models Clin Pharmacol Ther 83 909 912 18388873 10.1038/clpt.2008.52 1:CAS:528:DC%2BD1cXlvFOrtb0%3D (Pubitemid 351704927)
34. J Yang DE Mager RM Straubinger 2010 Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems AAPS J 12 1 10 19902363 10.1208/s12248-009-9155-7 1:CAS:528: DC%2BC3cXisVGrtrw%3D
35. Kalicki RM, Lledó R, Karlsson MO. Modeling of red blood cell (RBC) life-span (LS) in a hematologically normal population, 18th Population Approach Group in Europe (PAGE) meeting. St. Petersburg, Russia, 2009.
36. SA Landaw 1988 Factors that accelerate or retard red blood cell senescence Blood Cells 14 47 67 3052634 1:STN:280:DyaL1M%2FislWnsg%3D%3D
37. Krzyzanski W. Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models. J Pharmacokinet Pharmacodyn. 2010. doi: 10.1007/s10928-010-9183-z.